Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/67248
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Estevão-Pereira, Helena | por |
dc.contributor.author | Lobo, João | por |
dc.contributor.author | Salta, Sofia | por |
dc.contributor.author | Amorim, Maria | por |
dc.contributor.author | Lopes, Paula | por |
dc.contributor.author | Cantante, Mariana | por |
dc.contributor.author | Reis, Berta | por |
dc.contributor.author | Antunes, Luís | por |
dc.contributor.author | Castro, Fernando | por |
dc.contributor.author | Palma de Sousa, Susana | por |
dc.contributor.author | Gonçalves, Céline S. | por |
dc.contributor.author | Costa, Bruno Marques | por |
dc.contributor.author | Henrique, Rui | por |
dc.contributor.author | Jerónimo, Carmen | por |
dc.date.accessioned | 2020-10-02T11:18:09Z | - |
dc.date.available | 2020-10-02T11:18:09Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Estevão-Pereira, H., Lobo, J., Salta, S., Amorim, M., et. al. (2019). Overexpression of circulating MiR-30b-5p identifies advanced breast cancer. Journal of translational medicine, 17(1), 435 | por |
dc.identifier.uri | https://hdl.handle.net/1822/67248 | - |
dc.description.abstract | Breast cancer (BrC) remains the leading cause of cancer-related death in women, mainly due to recurrent and/or metastatic events, entailing the need for biomarkers predictive of progression to advanced disease. MicroRNAs hold promise as noninvasive cancer biomarkers due to their inherent stability and resilience in tissues and bodily fluids. There is increasing evidence that specific microRNAs play a functional role at different steps of the metastatic cascade, behaving as signaling mediators to enable the colonization of a specific organ. Herein, we aimed to evaluate the biomarker performance of microRNAs previously reported as associated with prognosis for predicting BrC progression in liquid biopsies. Background Breast cancer (BrC) remains the leading cause of cancer-related death in women, mainly due to recurrent and/or metastatic events, entailing the need for biomarkers predictive of progression to advanced disease. MicroRNAs hold promise as noninvasive cancer biomarkers due to their inherent stability and resilience in tissues and bodily fluids. There is increasing evidence that specific microRNAs play a functional role at different steps of the metastatic cascade, behaving as signaling mediators to enable the colonization of a specific organ. Herein, we aimed to evaluate the biomarker performance of microRNAs previously reported as associated with prognosis for predicting BrC progression in liquid biopsies. Methods Selected microRNAs were assessed using a quantitative reverse transcription-polymerase chain reaction in a testing cohort of formalin-fixed paraffin-embedded primary (n = 16) and metastatic BrC tissues (n = 22). Then, miR-30b-5p and miR-200b-3p were assessed in a validation cohort #1 of formalin-fixed paraffin-embedded primary (n = 82) and metastatic BrC tissues (n = 93), whereas only miR-30b-5p was validated on a validation cohort #2 of liquid biopsies from BrC patients with localized (n = 20) and advanced (n = 25) disease. ROC curve was constructed to evaluate prognostic performance. Results MiR-30b-5p was differentially expressed in primary tumors and paired metastatic lesions, with bone metastases displaying significantly higher miR-30b-5p expression levels, paralleling the corresponding primary tumors. Interestingly, patients with advanced disease disclosed increased circulating miR-30b-5p expression compared to patients with localized BrC. Conclusions MiR-30b-5p might identify BrC patients at higher risk of disease progression, thus, providing a useful clinical tool for patients’ monitoring, entailing earlier and more effective treatment. Nonetheless, validation in larger multicentric cohorts is mandatory to confirm these findings. | por |
dc.description.sponsorship | Research Center of Portuguese Oncology Institute of Porto (PI 74-CI-IPOP-19-2016). JL and CSG are supported by a PhD fellowship from FCT - Fundação para a Ciência e Tecnologia (SFRH/ BD/132751/2017 and SFRH/BD/92786/2013, respectively). SS is supported by a PhD fellowship IPO/ESTIMA-1 NORTE-01-0145-FEDER-000027. BMC is funded by FCT-Fundação para a Ciência e a Tecnologia (IF/00601/2012) | por |
dc.language.iso | eng | por |
dc.publisher | BioMed Central (BMC) | por |
dc.rights | openAccess | por |
dc.subject | Adult | por |
dc.subject | Aged | por |
dc.subject | Biomarkers, Tumor | por |
dc.subject | Breast Neoplasms | por |
dc.subject | Circulating MicroRNA | por |
dc.subject | Cohort Studies | por |
dc.subject | Female | por |
dc.subject | Humans | por |
dc.subject | Liquid Biopsy | por |
dc.subject | MicroRNAs | por |
dc.subject | Middle Aged | por |
dc.subject | Neoplasm Staging | por |
dc.subject | Prognosis | por |
dc.subject | ROC Curve | por |
dc.subject | Gene Expression Regulation, Neoplastic | por |
dc.subject | Breast cancer | por |
dc.subject | Metastasis | por |
dc.subject | Biomarkers | por |
dc.title | Overexpression of circulating MiR-30b-5p identifies advanced breast cancer | por |
dc.type | article | por |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://link.springer.com/article/10.1186/s12967-019-02193-y#citeas | por |
oaire.citationIssue | 435 | por |
oaire.citationVolume | 17 | por |
dc.identifier.eissn | 1479-5876 | - |
dc.identifier.doi | 10.1186/s12967-019-02193-y | por |
dc.identifier.pmid | 31888645 | por |
dc.subject.fos | Ciências Médicas::Medicina Básica | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Journal of Translational Medicine | por |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
10.1186_s12967-019-02193-y.pdf | 1,35 MB | Adobe PDF | Ver/Abrir |